Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.

Rhea-AI Summary

Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.

The event is scheduled for June 4, 2026 at 2:00 PM ET, with a live and archived webcast available on Aclaris’ website for at least 30 days.

Argus May 28 session

-0.22% close to close Open Argus

Details

News Market Reaction – ACRS

On May 28, the day this news came out, ACRS closed 0.22% below the previous close.

Data tracked by StockTitan Argus for the May 28 session.

Market Context

This announcement highlights Aclaris’ continued presence at major investor and industry meetings, wi...

Analysis

This announcement highlights Aclaris’ continued presence at major investor and industry meetings, with a Jefferies Global Healthcare Conference fireside chat on June 4, 2026 at 2:00 PM ET. It follows a series of clinical and financial updates in April and May, including positive ATI‑052 Phase 1a data and Q1 2026 results. The webcast, available for at least 30 days, offers a chance to monitor management’s latest commentary on pipeline progress and strategy.

Key Figures

Conference date: June 4, 2026 Presentation time: 2:00 PM ET Webcast availability: At least 30 days

Conference date

June 4, 2026

Jefferies Global Healthcare Conference fireside chat

Presentation time

2:00 PM ET

Scheduled time for fireside chat

Webcast availability

At least 30 days

Archived webcast on company website

Historical Context

5 past events · Latest: May 08

5 events

1. May 08

   Conference participation

   24h Move

   +1.4%

   Announced presentation at Bank of America Healthcare Conference with webcast access.

2. May 07

   Earnings & update

   24h Move

   +1.7%

   Q1 2026 results with positive ATI-052 data and strong cash position through 2028.

3. Apr 28

   Clinical data update

   24h Move

   -4.3%

   Positive full top-line Phase 1a ATI-052 results and ATI-2138 indication decision.

4. Apr 27

   Upcoming data call

   24h Move

   -4.3%

   Planned April 28 clinical update webcast for ATI-052 and ATI-2138 programs.

5. Apr 08

   Conference participation

   24h Move

   +5.3%

   Participation in H.C. Wainwright inflammatory skin disease conference with webcast.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Aclaris Therapeutics (NASDAQ:ACRS) present at the 2026 Jefferies Global Healthcare Conference?

Aclaris Therapeutics will participate in a fireside chat on Thursday, June 4, 2026, at 2:00 PM ET. According to Aclaris, the session is part of the 2026 Jefferies Global Healthcare Conference held in New York, NY.

How can investors access the Aclaris Therapeutics (ACRS) webcast from the 2026 Jefferies Healthcare Conference?

Investors can access a live and archived webcast on the Events page of the Aclaris website. According to Aclaris, the webcast link will be hosted at www.aclaristx.com and remain available for at least 30 days.

Will a replay of the Aclaris Therapeutics (ACRS) Jefferies 2026 conference fireside chat be available?

Yes, a replay will be available as an archived webcast on Aclaris’ website. According to Aclaris, the archived webcast of the June 4, 2026 fireside chat will remain online on the Events page for at least 30 days.

Who will represent Aclaris Therapeutics (ACRS) at the 2026 Jefferies Global Healthcare Conference fireside chat?

Aclaris’ Chief Executive Officer Dr. Neal Walker and other senior leadership team members will participate. According to Aclaris, they will join the fireside chat session scheduled for June 4, 2026, at 2:00 PM ET in New York.

Where will the Aclaris Therapeutics (ACRS) 2026 Jefferies conference event take place?

The fireside chat will take place in New York, NY, as part of the 2026 Jefferies Global Healthcare Conference. According to Aclaris, investors can attend virtually via live webcast hosted on the Events page of its corporate website.

What type of company is Aclaris Therapeutics (NASDAQ:ACRS) participating in the 2026 Jefferies Healthcare Conference?

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases. According to Aclaris, it is developing novel product candidates and will discuss its business in a fireside chat at the 2026 Jefferies Global Healthcare Conference.